Patents by Inventor Terence R. Jones
Terence R. Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110065640Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivates, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.Type: ApplicationFiled: August 30, 2010Publication date: March 17, 2011Applicant: Angstrom Pharmaceuticals, Inc.Inventors: Andrew P. Mazar, Terence R. Jones
-
Patent number: 7807621Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.Type: GrantFiled: November 15, 2006Date of Patent: October 5, 2010Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Andrew P. Mazar, Terence R. Jones
-
Publication number: 20090143303Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.Type: ApplicationFiled: November 15, 2006Publication date: June 4, 2009Inventors: Andrew P. Mazar, Terence R. Jones
-
Patent number: 6936587Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.Type: GrantFiled: September 3, 2003Date of Patent: August 30, 2005Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Andrew P. Mazar, Terence R. Jones
-
Patent number: 6896870Abstract: A uPAR-targeting protein or peptide is diagnostically or therapeutically labeled and used in methods of diagnosis of therapy. The labeled protein or peptide preferably has the following properties: it comprises at least 38 amino acid residues, including residues 13-30 of the uPAR-binding site of uPA; competes with labeled DFP-uPA for binding to a cell or molecule that has a binding site for uPA, and has an IC50 value of about 10 nM or less; and is not a fusion protein wherein the uPA peptide is fused to another non-uPA protein or peptide. Preferred molecules are uPA, scuPA, tcuPA, an N-terminal fragment of uPA, residues 1-135, an N-terminal fragment of uPA, residues 1-143, an N-terminal fragment of uPA, residues 1-43; or an N-terminal fragment of uPA, residues 4-43. Detectable labels include a radionuclide, a PET-imageable agent, an MRI-imageable agent, a fluorescer, a fluorogen, a chromophore, a chromogen, a phosphorescer, a chemiluminescer or a bioluminescer.Type: GrantFiled: September 27, 2000Date of Patent: May 24, 2005Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Andrew P. Mazar, Terence R. Jones
-
Publication number: 20040204348Abstract: uPAR-targeting cyclic peptide compounds have 11 amino acids that correspond to human uPA(20-30) [SEQ ID NO:2], or are substitution variants at selected positions. The N and C terminal residues of these peptides are joined by a linking group L, so that the linear dimension between the &agr;-carbons of the first and the eleventh amino acids is between about 4 and 12 Angstrom units. These cyclic peptides may be further conjugated to diagnostic labels or therapeutic moieties such as radionuclides. Such compounds are useful for targeting uPAR expressed in pathological tissues and for inhibiting the binding of uPA to the uPAR. The pharmaceutical and therapeutic compositions inhibit cell migration, cell invasion, cell proliferation or angiogenesis, or induce apoptosis, and are thus useful for treating diseases or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, most notably cancer. The cyclic peptides are also used to detect and isolate cells expressing uPAR.Type: ApplicationFiled: December 22, 2003Publication date: October 14, 2004Applicant: The Angstrom Pharmaceuticals, Inc.Inventors: Terence R. Jones, David N. Haney, Janos Varga, Andrew P. Mazar
-
Patent number: 6696416Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis . The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.Type: GrantFiled: November 10, 1999Date of Patent: February 24, 2004Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Andrew P. Mazar, Terence R. Jones
-
Publication number: 20030166514Abstract: Cyclic peptide compounds having 11 amino acids joined by a linking unit L, such that the linear dimension between the C&agr; carbon of the first amino acid and the C&agr; carbon of eleventh amino acid is between about 4 and 12 Ångstrom units; are useful for inhibiting the binding of uPA to the uPAR receptor.: Methods for using the cyclic peptide compounds, and compositions containing them, for inhibiting the growth or metastasis of cancerous tumors are also disclosed.Type: ApplicationFiled: January 22, 2003Publication date: September 4, 2003Inventors: Terence R. Jones, David N. Haney, Janos Varga
-
Publication number: 20030027768Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.Type: ApplicationFiled: September 6, 2002Publication date: February 6, 2003Inventors: Andrew P. Mazar, Terence R. Jones
-
Patent number: 6514710Abstract: Cyclic peptide compounds having 11 amino acids joined by a linking unit L, such that the linear dimension between the C&agr; carbon of the first amino acid and the C&agr; carbon of eleventh amino acid is between about 4 and 12 Ångstrom units; are useful for inhibiting the binding of uPA to the uPAR receptor. Methods for using the cyclic peptide compounds, and compositions containing them, for inhibiting the growth or metastasis of cancerous tumors are also disclosed.Type: GrantFiled: April 5, 1999Date of Patent: February 4, 2003Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Terence R. Jones, David N. Haney, Janos Varga
-
Patent number: 6277818Abstract: uPAR-targeting cyclic peptide compounds have 11 amino acids that correspond to human uPA(20-30) [SEQ ID NO:2], or are substitution variants at selected positions. The N and C terminal residues of these peptides are joined by a linking group L, so that the linear dimension between the a carbons of the first and the eleventh amino acids is between about 4 and 12 Ångstrom units. These cyclic peptides may be further conjugated to diagnostic labels or therapeutic moieties such as radionuclides. Such compounds are usefull for targeting uPAR expressed in pathological tissues and for inhibiting the binding of uPA to the uPAR. The pharmaceutical and therapeutic compositions inhibit cell migration, cell invasion, cell proliferation or angiogenesis, or induce apoptosis, and are thus useful for treating diseases or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, most notably cancer. The cyclic peptides are also used to detect and isolate cells expressing uPAR.Type: GrantFiled: October 29, 1998Date of Patent: August 21, 2001Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Andrew P. Mazar, Terence R. Jones
-
Patent number: 5994309Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.Type: GrantFiled: July 25, 1997Date of Patent: November 30, 1999Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Andrew P. Mazar, Terence R. Jones
-
Patent number: 5942492Abstract: Cyclic peptide compounds having 11 amino acids joined by a linking unit L, such that the linear dimension between the C.sup..alpha. carbon of the first amino acid and the C.sup..alpha. carbon of eleventh amino acid is between about 4 and 12 .ANG.ngstrom units; are useful for inhibiting the binding of uPA to the uPAR receptor. Methods for using the cyclic peptide compounds, and compositions containing them, for inhibiting the growth or metastasis of cancerous tumors are also disclosed.Type: GrantFiled: November 12, 1996Date of Patent: August 24, 1999Assignee: Angstrom Pharmaceuticals, Inc.Inventors: Terence R. Jones, David N. Haney, Janos Varga
-
Patent number: 5707992Abstract: Quinazoline compounds which demonstrate antiproliferative activity, such as antitumor activity, processes of preparing these compounds, pharmaceutical compositions containing these compounds, and the use of these compounds. These compounds inhibit the growth and proliferation of the cells of higher organisms and microorganisms, such as bacteria, yeasts and fungi. Preferred quinazoline compounds are capable of inhibiting the enzyme thymidylate synthase. Effects derived from the inhibition of the enzyme thymidylate synthase include those discussed above.Type: GrantFiled: April 7, 1995Date of Patent: January 13, 1998Assignee: Agouron Pharmaceuticals, Inc.Inventors: Stephen E. Webber, Ted M. Bleckman, John Attard, Terence R. Jones, Michael D. Varney
-
Patent number: 5574039Abstract: The invention relates to TS-inhibiting compounds of the formula ##STR1## where W is an alkylene group; D is a structure having two rings that are unsubstituted or substituted, where (i) one ring is a phenyl ring and (ii) the other ring is a phenyl ring or a 6-membered heterocyclic ring; R is a hydrogen atom or an alkyl group; and X and Y together form ##STR2## and to salts of these compounds. The moiety W can be CH.sub.2, and D can be a phenyl ring bridged through a sulfonyl group to another ring.Type: GrantFiled: September 22, 1994Date of Patent: November 12, 1996Assignee: Agouron Pharmaceuticals, Inc.Inventors: Michael D. Varney, Gifford P. Marzoni, Cynthia L. Palmer, Judith P. Deal, Terence R. Jones
-
Patent number: 5430148Abstract: Quinazoline compounds which demonstrate antiproliferative activity, such as antitumor activity, processes of preparing these compounds, pharmaceutical compositions containing these compounds, and the use of these compounds. These compounds inhibit the growth and proliferation of the cells of higher organisms and microorganisms, such as bacteria, yeasts and fungi. Preferred quinazoline compounds are capable of inhibiting the enzyme thymidylate synthase. Effects derived from the inhibition of the enzyme thymidylate synthase include those discussed above.Type: GrantFiled: March 31, 1992Date of Patent: July 4, 1995Assignee: Agouron Pharmaceuticals, Inc.Inventors: Stephen E. Webber, Ted M. Bleckman, John Attard, Terence R. Jones, Michael D. Varney
-
Patent number: 5236927Abstract: A compound of formula I: ##STR1## wherein R is hydrogen; oran alkyl, alkenyl or alkynyl group of up to 6 carbon atoms; nis O; 1 or 2; Z represents --CH.dbd.CH-- or --S--; each X independently represents halogeno, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, nitro or trifluoromethyl; and Y represents a group of formula: ##STR2## or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: December 12, 1990Date of Patent: August 17, 1993Assignee: National Research Development CorporationInventors: Terence R. Jones, Ann L. Jackman, David R. Newell
-
Patent number: 4564616Abstract: Quinazoline derivatives of formula: ##STR1## wherein R represents: (1) a straight or branched chain unsaturated hydrocarbon group, or(2) a straight or branched chain saturated or unsaturated hydrocarbon group which is substituted by at least one: heteroatom, the or each heteroatom being halogeno when R is a C.sub.1 hydrocarbon group; or saturated carbocyclic group; or group containing at least one heteroatom, the or each heteroatom being O, N or S when R contains a cyclic group; andn is O or an integer of 1-4;X or, when n is an integer of at least 2, each X independently, represents a halogeno, C.sub.1 -C.sub.4 alkyl, aryl or aralkyl group or a group including at least one heteroatom; andY represents a group of formula: ##STR2## wherein m.gtoreq.1 (poly-L-glutamates); and the pharmaceutically acceptable salts and esters thereof, which are suitable as anti-cancer agents.Type: GrantFiled: March 20, 1984Date of Patent: January 14, 1986Assignee: National Research Development CorporationInventors: Terence R. Jones, Kenneth R. Harrap, Alan H. Calvert
-
Patent number: 4447608Abstract: Quinazoline derivatives of formula: ##STR1## wherein R represents: (1) a straight or branched chain unsaturated hydrocarbon group, or(2) a straight or branched chain saturated or unsaturated hydrocarbon group which is substituted by at least one: heteroatom, the or each heteroatom being halogeno when R is a C.sub.1 hydrocarbon group; or saturated carbocyclic group; or group containing at least one heteroatom, the or each heteroatom being O, N or S when R contains a cyclic group; andn is 0 or an integer of 1-4;X or, when n is an integer of at least 2, each Xindependently, represents a halogeno, C.sub.1 -C.sub.4 alkyl, aryl or aralkyl group or a group including at least one heteroatom; andY represents a group of formula: ##STR2## wherein m.gtoreq.1 (poly-L-glutamates); and the pharmaceutically acceptable salts and esters thereof, which are suitable as anti-cancer agents.Type: GrantFiled: October 19, 1982Date of Patent: May 8, 1984Assignee: National Research Development CorporationInventors: Terence R. Jones, Kenneth R. Harrap, Alan H. Calvert